Replimune Group (NASDAQ:REPL) Given New $17.00 Price Target at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its price target lifted by JPMorgan Chase & Co. from $14.00 to $17.00 in a report published on Tuesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities research analysts also recently commented on the company. Wedbush restated an outperform rating and issued a $16.00 target price on shares of Replimune Group in a research report on Thursday, June 6th. Roth Capital upgraded shares of Replimune Group to a strong-buy rating in a research note on Tuesday, August 27th. HC Wainwright reissued a buy rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Monday, September 16th. Roth Mkm began coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a buy rating and a $17.00 price objective on the stock. Finally, Barclays boosted their target price on Replimune Group from $13.00 to $17.00 and gave the company an overweight rating in a report on Friday, June 7th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Buy and an average price target of $16.80.

Replimune Group Stock Performance

Shares of REPL stock opened at $11.16 on Tuesday. The business’s 50 day moving average is $10.34 and its two-hundred day moving average is $8.51. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.14. The company has a market capitalization of $685.39 million, a P/E ratio of -3.44 and a beta of 1.22. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. Analysts expect that Replimune Group will post -3.11 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group in the second quarter valued at $57,000. Cubist Systematic Strategies LLC increased its stake in shares of Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares during the last quarter. Algert Global LLC grew its stake in shares of Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after buying an additional 4,340 shares during the period. Millennium Management LLC increased its stake in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Replimune Group during the second quarter valued at approximately $443,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.